000124429 001__ 124429
000124429 005__ 20240228145514.0
000124429 0247_ $$2doi$$a10.1007/s00259-017-3711-7
000124429 0247_ $$2pmid$$apmid:28497198
000124429 0247_ $$2ISSN$$a0340-6997
000124429 0247_ $$2ISSN$$a1432-105X
000124429 0247_ $$2ISSN$$a1619-7070
000124429 0247_ $$2ISSN$$a1619-7089
000124429 0247_ $$2altmetric$$aaltmetric:20117199
000124429 037__ $$aDKFZ-2017-01306
000124429 041__ $$aeng
000124429 082__ $$a610
000124429 1001_ $$aAfshar-Oromieh, Ali$$b0$$eFirst author
000124429 245__ $$aDiagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.
000124429 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2017
000124429 3367_ $$2DRIVER$$aarticle
000124429 3367_ $$2DataCite$$aOutput Types/Journal article
000124429 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660303821_22214
000124429 3367_ $$2BibTeX$$aARTICLE
000124429 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124429 3367_ $$00$$2EndNote$$aJournal Article
000124429 520__ $$aSince the clinical introduction of (68)Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort.We performed a retrospective analysis of 1007 consecutive patients who were scanned with (68)Ga-PSMA-11 PET/CT (1 h after injection) from January 2014 to January 2017 to detect recurrent disease. Patients with untreated primary PCa or patients referred for PSMA radioligand therapy were excluded. The possible effects of different variables including PSA level and PSA doubling time (PSADT), PSA velocity (PSAVel), Gleason score (GSC, including separate analysis of GSC 7a and 7b), ongoing androgen deprivation therapy (ADT), patient age and amount of injected activity were evaluated.In 79.5% of patients at least one lesion with characteristics suggestive of recurrent PCa was detected. A pathological (positive) PET/CT scan was associated with PSA level and ADT. GSC, amount of injected activity, patient age, PSADT and PSAVel were not associated with a positive PET/CT scan in multivariate analysis.(68)Ga-PSMA-11 PET/CT detects tumour lesions in a high percentage of patients with recurrent PCa. Tumour detection is clearly associated with PSA level and ADT. Only a tendency for an association without statistical significance was found between higher GSC and a higher probability of a pathological PET/CT scan. No associations were found between a pathological (68)Ga-PSMA-11 PET/CT scan and patient age, amount of injected activity, PSADT or PSAVel.
000124429 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000124429 588__ $$aDataset connected to CrossRef, PubMed,
000124429 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b1
000124429 7001_ $$aGiesel, Frederik L$$b2
000124429 7001_ $$aKratochwil, Clemens$$b3
000124429 7001_ $$aMier, Walter$$b4
000124429 7001_ $$aHaufe, Sabine$$b5
000124429 7001_ $$aDebus, Nils$$b6
000124429 7001_ $$0P:(DE-He78)331382460d902d1341dc73db8b990f97$$aEder, Matthias$$b7
000124429 7001_ $$0P:(DE-HGF)0$$aEisenhut, Michael$$b8
000124429 7001_ $$0P:(DE-He78)3373acf5d3b93adfd9ea973cf2d218aa$$aSchäfer, Martin$$b9
000124429 7001_ $$0P:(DE-He78)4f3bf0db0166b782272f523c85369931$$aNeels, Oliver$$b10
000124429 7001_ $$aHohenfellner, Markus$$b11
000124429 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, Klaus$$b12
000124429 7001_ $$aKauczor, Hans-Ulrich$$b13
000124429 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b14
000124429 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b15$$eLast author
000124429 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-017-3711-7$$gVol. 44, no. 8, p. 1258 - 1268$$n8$$p1258 - 1268$$tEuropean journal of nuclear medicine and molecular imaging$$v44$$x1619-7089$$y2017
000124429 909CO $$ooai:inrepo02.dkfz.de:124429$$pVDB
000124429 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000124429 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)331382460d902d1341dc73db8b990f97$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000124429 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000124429 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3373acf5d3b93adfd9ea973cf2d218aa$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000124429 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4f3bf0db0166b782272f523c85369931$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000124429 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000124429 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aExternal Institute$$b14$$kExtern
000124429 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000124429 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000124429 9141_ $$y2017
000124429 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000124429 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124429 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000124429 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000124429 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000124429 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000124429 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124429 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000124429 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124429 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000124429 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000124429 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000124429 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000124429 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000124429 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000124429 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x2
000124429 980__ $$ajournal
000124429 980__ $$aVDB
000124429 980__ $$aI:(DE-He78)E060-20160331
000124429 980__ $$aI:(DE-He78)C060-20160331
000124429 980__ $$aI:(DE-He78)E030-20160331
000124429 980__ $$aUNRESTRICTED